Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge

Table 1 Characterization of CYT-IVAC hemagglutinin and cytokine content

Vaccine	HA pixel density*	HAU/μg of vaccine	Total cytokine (ng/μg vaccine)**	Bioactive cytokine (pg/μg vaccine)***
PR/8/34 w.t.	5835.4	16	NA	NA
PR/8/34 GM-CSF/HA	6407.9	16	185 ± 21	87.3
PR/8/34 IL-2/HA	5562.9	32	4.92 ± 0.3	411
PR/8/34 IL-4/HA	6090.4	32	176 ± 24	456

* Pixel density of HA specific chemiluminescent signal following equal loading of total viral protein
** Quantitation of virus-incorporated cytokine on protein level based on standard curve of recombinant cytokine (ng of cytokine per ug of vaccine)
*** Quantitation of virus-incorporated cytokine on bioactive level based on standard curve of recombinant cytokine (pg of cytokine per ug of vaccine)

ISSN: 1743-422X